Jeff Stark, MD, Vice President and Head of Immunology at UCB discusses the recent U.S. Food and Drug Administration approval of bimekizumab-bkzx (Bimzelx, UCB) for the treatment of moderate-to-severe hidradenitis suppurativa (HS) in adults and what it means to the HS community.
